Thyroid

Role of [18F]-Fluorodeoxy-D-Glucose Positron Emission Tomography and Computed Tomography in the Early Detection of Persistent/Recurrent Thyroid Carcinoma in Intermediate-to-High Risk Patients Following Initial Radioactive Iodine Ablation Therapy

Published in Volume: 22 Issue 2: February 1, 2012
Online Ahead of Print: January 6, 2012

Author information
Min-Hee Kim,1 Joo Hyun O,2 Sun Hee Ko,1 Ja-Seong Bae,3 Dong-Jun Lim,1 Sung-Hoon Kim,2 Ki-Hyun Baek,1 Jong-Min Lee,1 Moo-Il Kang,1 Bong-Yun Cha,1 and Kwang-Woo Lee1
1Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
2Department of Nuclear Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
3Department of Surgery, College of Medicine, The Catholic University of Korea, Seoul, Korea.

Address correspondence to:
Dong-Jun Lim, M.D.
Division of Endocrinology and Metabolism
Department of Internal Medicine
Seoul St. Mary's Hospital
The Catholic University of Korea
College of Medicine
#505 Banpo-Dong, Seocho-Gu
Seoul 137-701
Korea
E-mail: ldj6026@catholic.ac.kr

This study was presented in abstract form at Korean Endocrine Society's 2010 Annual Autumn Symposium, Daegu, Korea.

ABSTRACT

Background: Positron emission tomography/computed tomography (PET/CT) scan has a role in the surveillance of patients with a history of thyroid carcinoma. Its efficacy after remnant ablation as far as detecting persistent or recurrent thyroid carcinoma before other surveillance methods is not known, however. In intermediate-to-high risk thyroid carcinoma patients we studied whether PET/CT scan, performed 6–12 months after the
first remnant ablation, could provide more information than ultrasonography (US) and thyrotropin-stimulated serum thyroglobulin (Tg) determination with diagnostic whole-body scan (DxWBS).

**Methods:** We studied 71 subjects with differentiated thyroid cancer (DTC) who were intermediate-to-high risk for persistent/recurrent disease and who had received PET/CT scan, US, and DxWBS simultaneously with stimulated Tg levels 6–12 months after remnant ablation. To evaluate the diagnostic efficacy of PET/CT scan, the sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy were calculated.

**Results:** Ten subjects (14%) had persistent/recurrent disease detected 6–12 months after remnant ablation. Persistence/recurrence was detected in nine (12.7%) of these patients by conventional methods, including US and DxWBS, along with stimulated Tg levels. The remaining case was detected solely by a PET/CT scan, which showed a mediastinal prevascular lesion; this was confirmed by a therapeutic WBS after additional radioiodine therapy. Among the six patients whose PET/CT scan showed positive results, five had persistent/recurrent disease. The sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy of PET/CT scan for detecting persistent/recurrent thyroid carcinoma were 50%, 98.4%, 83.3%, 92.3%, and 91.5%, respectively.

**Conclusion:** In intermediate-to-high risk patients with DTC seen 6–12 months after their first remnant ablation, there is almost no complementary role for adding a PET/CT scan to conventional follow-up methods, an US and a DxWBS simultaneously with stimulated Tg levels.